These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33283576)

  • 1. Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.
    Ye Y; Zhang FT; Wang XY; Tong HX; Zhu YT
    J Am Heart Assoc; 2020 Dec; 9(24):e017876. PubMed ID: 33283576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Chinese herbal medicine for tPA thrombolysis in experimental stroke: A systematic review and meta-analysis.
    Ye Y; Zhu YT; Xin XY; Zhang JC; Zhang HL; Li D
    Phytomedicine; 2022 Jun; 100():154072. PubMed ID: 35349833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis.
    Ye Y; Zhu YT; Tong HX; Han JY
    Front Pharmacol; 2020; 11():615166. PubMed ID: 33424615
    [No Abstract]   [Full Text] [Related]  

  • 4. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
    Lapchak PA; Araujo DM; Song D; Zivin JA
    Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
    Liu DL; Hong Z; Li JY; Yang YX; Chen C; Du JR
    J Neuroinflammation; 2021 Jun; 18(1):143. PubMed ID: 34162400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
    Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
    Ishiguro M; Kawasaki K; Suzuki Y; Ishizuka F; Mishiro K; Egashira Y; Ikegaki I; Tsuruma K; Shimazawa M; Yoshimura S; Iwama T; Hara H
    Neuroscience; 2012 Sep; 220():302-12. PubMed ID: 22710066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
    J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
    García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
    Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
    Lapchak PA; Araujo DM; Song D; Wei J; Purdy R; Zivin JA
    Stroke; 2002 Jun; 33(6):1665-70. PubMed ID: 12053009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis.
    Guo Y; Yang Y; Zhou M; He L
    Stroke Vasc Neurol; 2018 Dec; 3(4):203-208. PubMed ID: 30637125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
    Simão F; Ustunkaya T; Clermont AC; Feener EP
    Blood; 2017 Apr; 129(16):2280-2290. PubMed ID: 28130211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
    J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
    Lapchak PA; Chapman DF; Zivin JA
    Stroke; 2001 Jan; 32(1):147-53. PubMed ID: 11136930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.
    Saposnik G; Fang J; Kapral MK; Tu JV; Mamdani M; Austin P; Johnston SC; ;
    Stroke; 2012 May; 43(5):1315-22. PubMed ID: 22308252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
    Adeoye O; Sucharew H; Khoury J; Vagal A; Schmit PA; Ewing I; Levine SR; Demel S; Eckerle B; Katz B; Kleindorfer D; Stettler B; Woo D; Khatri P; Broderick JP; Pancioli AM
    Stroke; 2015 Sep; 46(9):2529-33. PubMed ID: 26243231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
    Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
    Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.